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Abstract
Chronic pancreatitis (CP) is an inflammatory disorder charac-
terized by inflammation and fibrosis, resulting in a progressive and 
irreversible destruction of exocrine and endocrine pancreatic tis-
sue. Clinicians should attempt to classify patients into one of the six 
etiologic groups according to the TIGARO classification system. 
MRI/MRCP, if possible with secretin enhancement, is considered 
the imaging modality of choice for the diagnosis of early-stage dis-
ease. In CP, pain is the most disabling symptom, with a significant 
impact on quality of life. Pain should be assessed using the Izbicki 
score and preferably treated using the “pain ladder” approach. In 
painful CP, endoscopic therapy (ET) can be considered as early as 
possible. This procedure can be combined with extracorporeal 
shock-wave lithotripsy (ESWL) in the presence of large (> 4 mm), 
obstructive stone(s) in the pancreatic head, and with ductal stent-
ing in the presence of a single main pancreatic duct (MPD) stric-
ture in the pancreatic head with a markedly dilated MPD. Pancre-
atic stenting should be pursued for at least 12 months in patients 
with persistent pain relief. On-demand stent exchange should be 
the preferred strategy. The simultaneous placement of multiple, 
side-by-side, pancreatic stents can be recommended in patients 
with MPD strictures persisting after 12 months of single plastic 
stenting.
We recommend surgery in the following cases : a) technical fail-
ure of ET ; b) early (6 to 8 weeks) clinical failure ; c) definitive bili-
ary drainage at a later time point ; d) pancreatic ductal drainage 
when repetitive ET is considered unsuitable for young patients ; 
e) resection of an inflammatory pancreatic head when pancreatic 
cancer cannot be ruled out ; f) duodenal obstruction. Duodenopan-
createctomy or oncological distal pancreatectomy should be con-
sidered for patients with suspected malignancy. Pediatricians 
should be aware of and systematically search for CP in the differ-
ential diagnosis of chronic abdominal pain. As malnutrition is 
highly prevalent in CP patients, patients at nutritional risk should 
be identified in order to allow for dietary counseling and nutrition-
al intervention using oral supplements. Patients should follow a 
healthy balanced diet taken in small meals and snacks, with normal 
fat content. Enzyme replacement therapy is beneficial to symptom-
atic patients, but also in cases of subclinical insufficiency. Regular 
follow-up should be considered in CP patients, primarily to detect 
subclinical maldigestion and the development of pancreatogenic 
diabetes. Screening for pancreatic cancer is not recommended in 
CP patients, except in those with the hereditary form. (Acta gastro-
enterol. belg., 2014, 77, 47-65).
Chronic pancreatitis (CP) is an inflammatory disorder 
characterized by inflammation and fibrosis, resulting in a 
progressive and irreversible destruction of exocrine and 
endocrine pancreatic tissue, with pain often a predomi-
nant clinical symptom. Population-based epidemiologi-
cal data on CP is scarce, which is probably due to the 
difficulty in establishing a firm diagnosis at the early 
stage of the disease. Prevalence rates of about 26 to 28 
per 100,000 people have been reported in France and Ja-
pan (1,2). Time course data suggests that CP incidence is 
rising, most likely on account of increased alcohol con-
sumption and improved diagnostic techniques (3-5). No 
data on CP epidemiology and etiology in Belgium is 
available yet.
I. Etiology and risk factors of chronic pancrea-
titis
Statement : In every CP case, clinicians should at-
tempt to classify the patient – after a thorough patient 
anamnesis covering environmental factors, and per-
sonal and family history, and after standardized 
 biochemical, immunolo gical, and genetic testing, if 
 appropriate, as well as detailed imaging studies – into 
one of the six etiologic groups of the TIGARO classi-
fication
In earlier studies, alcohol was considered the main 
etiologic factor in calcifying CP. These older studies 
 concluded that most CP patients were men (70-90%), 
with heavy drinking being the most common etiology in 
70-80% of patients (5,6). During recent years, it has be-
come apparent that a number of other risk factors, includ-
ing hereditary and immunological factors, as well as in-
teractions between these risk factors, are crucial in CP 
pathogenesis. Major risk factors for CP can be classified 
into systems such as the TIGAR-O (7) classification, al-
lowing patients to be categorized into one of six groups 
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Groove pancreatitis or cystic dystrophy of the duode-
nal wall is considered when a typical clinical, endoscop-
ic, and radiologic pattern is observed, with significant 
thickening and cystic changes of the duodenal wall, 
along with a mass lesion between the duodenum and pan-
creatic head (15).
Genetic analysis for mutations in the cationic trypsin-
ogen gene (PRSS1) is only conducted in patients with 
hereditary pancreatitis or a family history of pancreatitis. 
The PRSS1-gene is considered a disease-causing gene. 
Yet other genes such as the cystic fibrosis transmem-
brane conductance regulator (CFTR) and serine protease 
inhibitor Kazal Type 1 (SPINK1) are considered disease-
modifying genes that may, together with other environ-
mental and genetic factors, play a role in the pathogenesis 
of distinct CP types, such as alcoholic and idiopathic 
CP (7,8,13).
II. Diagnosis of chronic pancreatitis
1. How should a diagnosis of early chronic pancreatitis 
be established ?
Statement : MRI/MRCP, if possible combined with 
 secretin enhancement, is the imaging modality of 
choice for diagnosing early chronic pancreatitis
Diagnosis of CP is usually made using imaging tech-
niques. Yet, in early stage CP, diagnosis by these means 
may be difficult as the morphological changes are mini-
mal (16,17). Magnetic resonance imaging (MRI) is more 
sensitive than computed tomography (CT) for detecting 
early CP stages, as signal changes can be picked up 
prior to morphological changes. Magnetic resonance 
cholangiopancreatography (MRCP) allows for excellent 
 visualization of the pancreatic ducts, with secretin en-
hancement providing an even better visualization of ab-
normalities of the pancreatic duct and its branches. MRI/
MRCP, if possible combined with secretin enhancement, 
according to the factor most strongly associated with 
their pancreatic disease (Table 1). The etiological classi-
fication of every individual CP patient undoubtedly re-
quires a thorough anamnesis covering environmental 
factors, as well as personal and family history, along with 
standardized laboratory evaluation, genetic testing, and 
detailed radiological studies, along with MRCP, CT, and 
ERCP (8-9).
For inclusion into the toxic alcohol abuse group, pa-
tients must exhibit a “heavy” alcohol drinking-pattern, 
consisting of at least four to five consumptions or 48 to 
60g of alcohol per day over several years. This alcohol 
amount is considered a threshold for developing alco-
holic CP (6,10,11). However, less than 10% of people 
who drink alcohol in excess develop the disease, suggest-
ing that other environmental and genetic factors interact 
with alcohol to amplify its toxicity. Smoking is consid-
ered an independent risk factor for CP pathogenesis and 
progression rate (5,6,10,11).
A diagnosis of idiopathic CP is established when no 
other clear etiology is identified, such as alcoholism, he-
reditary or familial, autoimmune pancreatitis, obstructive 
causes, or acute pancreatitis-associated CP.
Hereditary CP is considered when pancreatitis occurs 
in an individual from a family with a pancreatitis pheno-
type inherited through a disease-causing gene mutation 
expressed in an autosomal dominant pattern (12).
The diagnosis of autoimmune pancreatitis requires 
clinical and radiologic characteristics, as well as distinct 
serological/immunohistochemical IgG4 features. The 
Type 1 group is mainly characterized by high IgG4 con-
centrations and histological findings designated as lym-
phoplasmocytic sclerosing pancreatitis (LPSP). The 
Type 2 group is distinguished by a normal IgG4 concen-
tration and histological findings of idiopathic duct-cen-
tric pancreatitis (IDCP). Type I CP is part of the IgG4-
related spectrum, and may be accompanied by other 
IgG4-related diseases, whereas Type 2 is associated with 
ulcerative colitis (13,14).






Idiopathic Early onset  < 35 years
Late onset > 35 years
Genetic  PRSS1, CFTR, and SPINK1 mutations
Autoimmune Type I: IgG4-related disease
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While CP diagnosis is mainly based on imaging stud-
ies, functional pancreatic assessment is principally aimed 
at detecting gland insufficiency in patients with known 
pancreatic disease or after pancreatic surgery, assisting in 
the indication of enzyme substitution therapy, and over-
seeing the efficacy of this therapy (28). At present, there 
is only a limited role for function tests in the diagnosis of 
CP. These tests can, however, be of some help for CP 
diagnosis in cases with inconclusive morphological find-
ings associated with high clinical suspicion. MRCP after 
intravenous secretin (s-MRCP) administration enables 
assessment of exocrine pancreatic function based on 
quantification of duodenal filling, which is reduced in 
 patients with exocrine insufficiency. This study is less 
invasive than other direct function tests, yet appears to be 
sufficiently sensitive to identify patients with mild 
 exocrine pancreatic insufficiency (29-31).
4. Differential diagnosis
Statement : MRI and EUS are essential for the differ-
ential diagnosis of chronic pancreatitis with other 
 pancreatic masses or cystic lesions
Differentiation between mass-forming CP and other 
pancreatic lesions remains a challenge (31,32). MRI is 
superior to CT in visualizing tumors within pancreatic 
inflammation areas. While EUS produces high resolution 
images, this procedure cannot reliably differentiate ma-
lignant from inflammatory lesions due to the similar EUS 
appearance of adenocarcinoma and focal pancreatitis. 
Even when FNA is used in conjunction with EUS, a cy-
tological evaluation of pancreatic tissue in the setting of 
chronic inflammation proves highly difficult, as inflam-
matory infiltrates may obscure or simulate pancreatic 
malignancy. EUS-FNA sensitivity is therefore much 
lower in the CP setting (54%-73%) (33). New EUS im-
aging techniques, such as elastography and contrast-en-
hanced harmonic EUS (CEH-EUS), have been proposed 
so as to overcome these limitations. Recent meta-analy-
ses have shown high accuracy with both techniques, but 
their true diagnostic value for patients where FNA has 
failed, or in those with underlying CP, has not been con-
sistently proven (34,35).
Groove pancreatitis is a rare CP form affecting the 
duodenopancreatic groove. Its principal feature is the 
presence of cysts surrounded by inflammation and fibro-
sis in the intestinal wall. Differentiating this entity from 
infiltration by a pancreatic carcinoma may prove highly 
difficult. Diagnosis should rely on CT, MRI, the duode-
num’s endoscopic appearance, as well as EUS with 
FNA (36).
Auto-immune pancreatitis (AIP) may be difficult to 
differentiate from pancreatic adenocarcinoma. There is 
no single test that can reliably diagnose AIP. The diagno-
sis is based on a combination of imaging findings, 
 serology, other organ involvement, histology, and 
 response to corticosteroids (37). Intraductal papillary 
are thus the imaging modalities of choice to detect less 
advanced disease with the greatest reliability and mini-
mal invasiveness (18). Endoscopic ultrasound (EUS), 
which is more invasive, is the most sensitive imaging 
method for detecting minimal structural changes indica-
tive of CP, and may provide add-on value in uncertain 
cases (19). To standardize EUS features and thresholds 
for CP diagnosis, a consensus-based scoring system has 
been proposed (20). The so-called Rosemont classifica-
tion does not specifically address early-stage CP, and it is 
still unresolved whether ‘indeterminate for CP’ accord-
ing to this classification represents early-stage CP (21). 
In addition to low interobserver agreement amongst en-
dosonographers, it should also be mentioned that subtle 
abnormalities detected by EUS are not specific, as they 
have also been reported in the context of alcoholism, ad-
vanced age, male gender, obesity, and cigarette smok-
ing (22). Early-stage CP tends to be a focal, patchy dis-
ease that can be missed by image-guided biopsies, and 
tissue sampling (FNA or biopsy) is thus not recommend-
ed (23,24).
2. How should chronic pancreatitis be classified ?
Statement : There is no consensus on which clinical 
classification system is to be proposed for daily 
 practice
The main reason for the lack of guided strategies in 
CP management is the absence of a clinically applicable 
classification. In recent years, it has become clear that 
clinical decisions cannot be made solely on the type and 
degree of morphological abnormalities, but need to be 
based on clinical, functional, and imaging findings. Mul-
tiple classification systems have been proposed, however 
none of them have been extended to clinical practice or 
used as a standard for comparative studies (9, 25-27). In 
one of the more simple classifications (27), CP is sepa-
rated into four different stages :
I. Pre-clinical stage with absent or uncharacteristic 
symptoms ;
II. Recurrent acute episodes of pancreatitis without 
definite signs of CP ;
III. Further recurrent episodes with intermittent or 
constant pain in between and signs of CP, such as duct 
dilatation and pancreatic calcification on imaging ;
IV. Final stage, mostly without acute flares and ab-
sence or decreased frequency of pain, possibly associated 
with evidence of endocrine and exocrine insufficiency 
(burnout).
This classification is easily reproducible in clinical 
practice and more suitable for treatment purposes. 
3. Utility of pancreatic function testing for diagnosis
Statement : Pancreatic function tests have only a 
 limited value in the diagnosis of CP
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ries (43,49). Firstly, most patients exhibit an intermittent 
pain pattern that is characterized by pain-free intervals 
alternating with pain attacks. These attacks can range 
from mild and responding well to systemic analgesics to 
a more severe form requiring hospitalization and more 
invasive treatment options. On the other hand, other pa-
tients experience more continuous pain, which is at times 
complicated by acute flares. The second pattern often 
correlates with continued alcohol intake and is more fre-
quently observed in smokers. This latter patient group is 
more frequently hospitalized, with a significant higher 
number of sick days (49).
2. How should pain be objectively assessed ?
No objective instruments have been validated to esti-
mate the intensity of pain in CP patients. Numerical 
scales, such as the visual analog scale (VAS), are 
 commonly applied. In recent studies, the Izbicki score 
(Table 2) has been used. This specific score is based on 
the pain attack frequency, VAS-score, analgesic use, and 
duration of disease-related inability to work (50).
Pain obviously affects overall quality of life (QOL). 
Various questionnaires have been used to assess the im-
pact of pain on patient QOL (SF-12, SF-36, EORTC 
QLQ C-30, and GIQLY). The easiest evaluation tool in 
this respect is undoubtedly the SF-12, for this scale pro-
vides the same information as more extensive question-
naires, while being far less complicated (51).
3. How should pain be treated in chronic pancreatitis ?
Statement : Pain is the most disabling symptom in 
chronic pancreatitis, which significantly impacts 
QOL, and is caused by several pathophysiological 
mechanisms. It should be assessed using the Izbicki 
score. The “pain ladder” approach is recommended 
for pain treatment. In refractory cases, alternative 
treatments are available
As with all chronic pain syndromes, treating pain as-
sociated with CP may prove challenging. The WHO 
3-step (52) approach is used as standard when prescrib-
ing analgesics (the so-called “pain ladder”), yet 
paracetamol alone or in combination with non-steroidal 
anti-inflammatory drugs (NSAID) is rarely sufficient. A 
weak opioid may be added in the next step. Tramadol 
appears to be a logical choice, as this drug exhibits less 
opioid-induced side-effects like obstipation and sedation. 
However, a large percentage of patients experience nau-
sea and vomiting due to tramadol’s serotonergic activi-
ty (53). Anti-oxidants may be beneficial, yet clinical 
studies have shown mixed results (52,54). 
Endoscopic approaches, aimed at decompressing an 
obstructed pancreatic duct, are performed in the presence 
of stones or strictures. Short-term pain relief is readily 
achieved with such procedures, although more definite 
surgical interventions appear more effective for sustained 
analgesia (56-59). Celiac plexus infiltration with local 
mucinous neoplasms (IPMN) can be misdiagnosed for 
CP, as both conditions share similar features, such as di-
lated pancreatic ducts, cystic lesions, and even extensive 
calcifications. In rare cases, focal CP can also present as 
IPMN due to cystic dilatations of the branch ducts (38, 
39). In this context, CT, MRI/MRCP, and EUS are indi-
cated for diagnosis and differentiation of IPMN and 
CP (40). EUS-guided FNA enables sampling of cyst fluid 
contents for cytology and tumor markers. Cytology is 
usually non-contributive due to its low sensitivity and in-
sufficient sample volumes (41). ERCP and per oral pan-
creatoscopy can be useful in the evaluation of main duct 
type IPMN lesions and differentiation from CP (42).
III. Assessment of pain, complications, and mal-
nutrition in chronic pancreatitis
A. Pain in chronic pancreatitis
1. Which type and mechanism of pain is suspected ?
Most CP patients experience pain as one of the most 
dominant and disabling symptoms of their disease. How-
ever, some CP patients do not display any nociceptive 
symptoms at all. In a certain number, the pain wears off 
with time and tends to disappear at the stage of full scle-
rosis of the pancreas (43).
The pathophysiology of the different types of pain ob-
served in CP is probably multifactorial. A more visceral 
type of pain occurs when nociceptive receptors become 
sensitized due to high pressure in the pancreatic ducts or 
parenchyma. It has also been postulated that visceral pain 
can be induced by the secretion of pancreas enzymes or 
tissue ischemia (8,44-48). The various surgical and endo-
scopic drainage procedures performed in clinical practice 
are based on this principle. Although a large proportion 
of patients are (partly) relieved from pain after such pro-
cedures, there is also a group of patients suffering from 
CP and chronic pain who do not display significant 
changes in ductal or parenchymal pressure (8,47). The 
hypothesis that alcohol could have a direct nociceptive 
(pain inducing) effect is contradicted by the fact that a 
direct correlation between alcohol and pain has never 
been proven (48).
A peripheral neuropathic syndrome is also considered 
as playing a role. There is, indeed, evidence that the re-
ceptors involved in visceral sensitivity, such as TRPV1, 
GAP-43, and NGF, are increasingly expressed in the 
nerve endings within the pancreas of CP pa-
tients (8,45,46,48).
The current consensus clearly indicates that many of 
these patients suffer from a chronic pain syndrome due to 
the development of central nervous system sensitization 
and wind-up. In such cases, the pain syndrome should be 
treated as a disease entity, rather than a symptom arising 
from tissue injury (8,46).
In a broader sense, the temporal features of the pain 
syndrome in CP patients can be divided into two catego-
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tion). The size, number, content, and location of 
pseudocyst(s), the MPD anatomy and presence of associ-
ated ductal lesions (stones, strictures, or rupture), the 
communication of the pseudocyst with the pancreatic 
duct, the presence of associated vascular lesions like 
pseudoaneurysm or venous thrombosis, and any com-
pression of adjacent organs are all best delineated by 
means of magnetic resonance imaging (MRI and MRCP). 
These procedures are therefore recommended as essen-
tial tools in therapy planning (62).
Chronic pseudocyst(s) can be treated by endoscopic, 
percutaneous, or surgical drainage. Two endoscopic ap-
proaches have been described for pseudocyst drainage, 
namely through the papilla (transpapillary [TP] drainage) 
or gastrointestinal wall by creating a cystogastrostomy or 
cystoduodenostomy (transmural [TM] drainage), fol-
lowed in both cases by the insertion of one or more plas-
tic stents. TP drainage may be recommended if TM 
drainage is contraindicated or not feasible (e.g., signifi-
cant coagulopathy or no safe window due to intervening 
blood vessels secondary to portal hypertension), for 
small (< 6 cm) pseudocysts communicating with the pan-
creatic duct on pancreatography, for preprocedural 
MRCP, and when pancreatic duct obstruction (stricture 
or stone) or leaks must be addressed (63). When both TM 
and TP drainage are technically feasible, we currently fa-
vor TM drainage with the insertion of at least two dou-
ble-pigtail plastic stents, which should be left in place for 
at least 2 months or longer if MPD rupture (disconnected 
duct syndrome) is observed. The technical success rate of 
TM drainage was reported to be significantly higher for 
EUS-guided TM drainage compared to non-EUS-guided 
anesthetics or radiofrequency-induced denervation can 
also be applied in therapy-resistant pain syndromes. The 
use of neurodestructive methods with alcohol or phenol 
is contraindicated in CP on account of the high risk of 
severe deafferentation syndromes after such procedures.
Recently, spinal cord stimulation via epidurally-
placed leads at the T6-T7 level has resulted in therapeutic 
benefits in CP-associated pain (60).
B. Complications other than endocrine/exocrine 
pancreatic failure
The main complications of chronic pancreatitis are 
pseudocyst formation, common bile duct (CBD) obstruc-
tion, duodenal obstruction, cancer development, spleno-
porto-mesenteric thrombosis, and gastrointestinal bleed-
ing.
1. Pseudocysts
Statement : Endoscopic therapy, in particular EUS-
guided TM drainage, is the first-line therapy for un-
complicated chronic pseudocysts, for which treatment 
is indicated and which are within endoscopic reach
Pseudocyst formation is a common complication of 
CP, with a reported incidence of 20%-40%. Less than 
10% of these pseudocysts resolve spontaneously (61). 
Treatment is indicated for pseudocysts that cause symp-
toms (abdominal pain or early satiety), complications 
(infection, bleeding, or rupture), or compression of sur-
rounding organs (gastric, duodenal, or biliary obstruc-
Table 2. — IZBICKI pain score
                                                                                                                                    Points
Frequency of pain attacks
Daily                                                                                                                          100
Several times a week                                                                                                     75
Several times a month                                                                                                   50
Several times a year                                                                                                      25
None                                                                                                                              0
Visual analog scale (VAS) 
No pain                                                                                        Imaginative maximum of pain
   l---------------------------------------------------------------------------------------------------------l
0 points                                                                                                                      100 points
Analgesic medication*
Morphine                                                                                                                   100
Buprenorphine                                                                                                             80
Pethidine                                                                                                                     20
Tramadol                                                                                                                     15
Metamizole                                                                                                                   3
Acetylsalicyl acid                                                                                                          1
Duration of disease-related inability to work
Permanent                                                                                                                  100
	 1 year                                                                                                          75
	 1 month                                                                                                       50
	 1 week                                                                                                         25
No inability to work during the last year                                                                           0
* When drug combinations were used, the most potent analgesic was taken into account.
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caused by epithelial hyperplasia involving the uncovered 
portions, while these stents cannot be removed. In con-
trast, fully covered SEMS can be removed, and tempo-
rary treatment with covered SEMS has thus become an 
attractive option (74). In a proportion of CP patients with 
biliary strictures refractory to endoscopic stenting, by-
pass surgery (hepaticojejunostomy) is usually preferable 
to long-term stenting, especially for non-compliant pa-
tients with alcoholic CP. However, in non-operative can-
didates with high operative risk due to local (e.g., portal 
cavernous) or general conditions, fully covered SEMS 
are a therapeutic option.
3. Other rare complications
Vascular complications in the CP setting include 
pseudoaneurysm. In patients with both pseudoaneurysm 
and pseudocyst (75), the former should be treated using 
selective angiographic embolization prior to any pseudo-
cyst drainage attempt. 
In patients with left-sided portal hypertension due to 
splenic vein thrombosis, splenectomy or interventional 
radiology should only be performed in cases of proven 
variceal bleeding (67,73).
Duodenal obstruction, which occurs rarely (in approx-
imately 1% of CP cases), should be treated by surgery 
(bypass or resection in cases of inflammatory mass in the 
pancreatic head) (76).
For pancreatic ascites or pancreatic pleural effusion, 
conventional treatment strategies comprise bed rest with 
nutritional support using parenteral or enteral feeding, 
paracentesis, and somatostatin analogues. When support-
ive management fails, endoscopic intervention (pancre-
atic sphincterotomy or stenting) should be considered, 
with the aim of sealing off the leak and overcoming a 
distal ductal obstruction (76).
4. Inflammatory masses
Statement : In patients with a pancreatic mass or main 
pancreatic duct/common bile duct stricture, adequate 
work-up should be performed to reasonably rule out 
pancreatic cancer
Approximately one-third of CP patients undergoing 
surgery present with an inflammatory mass in the pancre-
atic head. We do not know the exact prevalence of such a 
mass in the entire CP population. From a radiological 
perspective, the pancreatic head is considered enlarged 
when the anterio-posterior diameter exceeds 4 cm. This 
enlargement may cause local complications, such as duo-
denal compression, vascular thrombosis, and biliary 
strictures. Nearly 50% of the patients with an enlarged 
pancreatic head experience episodes of jaundice due to 
common bile duct stenosis. Other local complications are 
listed in Table 3. Surgery is key in the treatment of com-
plications due to an inflammatory mass of the pancreatic 
head. As preferred techniques, we consider the Frey or 
Beger drainage-resection intervention (77).
TM drainage in two randomized controlled trials 
(RCT) (64,65). Multivariate analysis identified three fac-
tors predictive of a more favorable outcome after pseudo-
cyst TM drainage : pancreatic head localization of the 
cyst, drainage duration of more than 6 weeks, and inser-
tion of multiple double-pigtail stents (66). A randomized 
clinical trial also showed that systematic stent retrieval 
within 2 weeks of pancreatic fluid collection resolution 
resulted in a higher recurrence rate, mostly in patients 
with PD rupture (62,63). 
Percutaneous drainage should not be performed in 
chronic pseudocysts (67), excepting patients who are not 
candidates for other procedures (63). Compared with 
surgical cystogastrostomy, EUS-guided TM drainage of 
pseudocyst provided similar clinical results, at a lower 
cost, with shorter hospital stay, and improved quality of 
life (68,69).
2. Biliary stricture
Statement : CP-related biliary strictures can be treated 
with multiple 10F plastic stents for approximately 
12 months. Uncovered or partially covered SEMS 
should not be used. Fully covered stents are currently 
in evaluation in this setting
Common bile duct (CBD) stenosis is a result of pan-
creatic head inflammatory or fibrotic changes, or may be 
related to compression by a pancreatic pseudocyst. Its 
prevalence rates range from 3% to 45% of CP patients, 
but only about 10% of these patients actually develop 
symptoms related to biliary obstruction (70). Conserva-
tive management is recommended in asymptomatic pa-
tients with CBD dilatation yet presenting normal liver 
function tests (67). MRCP is the preferred imaging pro-
cedure for delineating the bile duct stricture and pancre-
atic duct anatomy, while ERCP is favored when interven-
tion is required. Endoscopic stenting of the CBD distal 
stricture is an effective approach for temporary biliary 
decompression in CP patients presenting with cholangi-
tis, persistent cholestasis, or obstructive jaundice.
The only predictive risk factor for failure of endoscop-
ic single plastic biliary stenting identified in CP patients 
was the presence of pancreatic head calcifications (71). 
On the other hand, concomitant acute pancreatitis at pre-
sentation was the only factor predictive of a successful 
outcome after biliary stenting (72). Long-term stricture 
resolution after stent removal in 350 patients treated with 
a single plastic stent (usually 10F) was reported in 10-
80% of cases (mean 31%) during follow-up periods rang-
ing from 14 to 58 months (73).
Long-term results were improved following the place-
ment of multiple (> or=3) plastic 10F stents, usually dur-
ing 1 year, with stricture resolution observed in 44-92% 
of cases (mean 62%) in the 12 to 48 months after stent 
removal (67,73,74). Uncovered and partially covered 
self-expandable metal stents (SEMS) are currently not 
recommended. This is due to the early stent occlusion 
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has the potential to improve both nutritional status and 
maldigestion. Parenteral nutrition should only be used in 
cases of GI-tract obstruction or as a supplement to en-
teral nutrition (78).
IV. Medical treatment of chronic pancreatitis
Statement : There is no specific medical treatment for 
chronic pancreatitis, apart from measures aimed at 
 compensating exocrine and endocrine insufficiency. 
Every effort should be focused on supporting the pa-
tient in stopping drinking and smoking
There is no specific medical treatment for CP, apart 
from treating pain and managing exocrine and endocrine 
insufficiency. First-line medical options mainly comprise 
appropriate dietary counseling, abstinence from alcohol 
and tobacco, adjunctive agents and pancreatic enzymes, 
as well as analgesic agents.
Every effort should be focused on supporting the 
 patient in stopping drinking and smoking. Abstinence 
from alcohol has a crucial impact on pain alleviation in 
patients with alcoholic pancreatitis. Abstainers exhibit a 
slower rate of pancreatic function deterioration and a 
 better response to therapeutic pain control than non- 
abstainers (84,85). It is difficult to distinguish the role of 
smoking from that of alcohol consumption in terms of 
CP etiology and clinical evolution, as cigarette smoking 
and alcoholic consumption are most often mutually in-
clusive (86,87). Moreover, alcohol withdrawal is rarely 
accompanied by smoking withdrawal. Combined with-
drawal of both toxic habits should perhaps be considered, 
rather than initially prioritizing alcohol withdrawal. 
Retro spective data indicating a beneficial effect of 
 smoking withdrawal in reducing pain and CP-related 
complications has led to the recommendation of smoking 
withdrawal for CP patients (28).
Increased oxidative stress has been implicated as a po-
tential mechanism in CP etiology and pathology. A num-
ber of studies have demonstrated that CP patients display 
a compromised antioxidant status, which may contribute 
to the enhanced oxidative state associated with the dis-
ease. Exocrine insufficiency leads to further deficiencies 
and impaired antioxidant status. Chronic use of oral anti-
oxidant supplements could help prevent painful CP re-
currences. The overall effectiveness of antioxidants has 
not however, been proven, and the best combination of 
agents and dosages is not yet clear (8,54,55, 88-90).
The exogenous pancreatic protease replacement for 
pain relief is based on the concept of the feedback inhibi-
tion of pancreatic exocrine secretion. In addition, it has 
been proposed that PERT can stimulate receptors in the 
proximal small intestine and trigger a negative feedback 
loop that suppresses baseline pancreatic secretion, 
 decreasing ductal pressures and therefore pain. A meta-
analysis conducted on published studies concluded that 
there was no significant benefit provided by pancreatic 
enzymes for pain relief in painful CP. Although 
C. Malnutrition
Statement : As malnutrition is highly prevalent in CP, 
patients at nutritional risk should be identified to allow 
for dietary counseling and nutritional intervention 
 using oral supplements 
CP results in exocrine and endocrine dysfunction, 
with negative effects on digestion and absorption of 
 nutrients. In CP patients, nutrition status may be further 
affected by poor dietary intake, often related to alcohol-
ism.
It is widely accepted that CP patients are often under-
nourished, although only a few well-conducted clinical 
studies have confirmed this assumption. In a study con-
ducted in a medical rehabilitation clinic setting, low BMI 
(< 20 kg/m2) and ongoing maldigestion were prevalent in 
32% of patients (78). A cross-sectional cohort study in-
volving 60 patients admitted to a Danish university gas-
troenterology department reported that 28% exhibited 
nutritional risk (NRS-2002 screening tool), despite still 
presenting with a normal BMI. Patients at nutritional risk 
had lower muscle mass (low fat-free mass index FFMi) 
and muscle strength (hand grip strength). A very low 
BMI (< 20) was associated with higher resting energy 
expenditure (79). Evaluation of body composition 
showed a decrease in lean body mass, reduced functional 
capacity, and reduced fat mass (energy store), which was 
significantly more pronounced in patients with severe 
exocrine pancreatic insufficiency compared to those with 
residual pancreatic function (80). Poor nutritional status 
clearly affected quality of life, as almost half of the pa-
tients suffered from moderate to severe fatigue (81). Fur-
thermore, specific deficiencies resulting in nutrition-re-
lated problems, such as diminished bone health, may be 
overlooked (82). 
These findings raise questions about what measures 
should be implemented for improving CP patient quality 
of life. A thorough nutritional assessment is undoubtedly 
necessary to establish a targeted nutrition and rehabilita-
tion plan. A randomized controlled trial compared di-
etary counselling to commercial dietary supplementation 
in undernourished (BMI of < 18.5kg/m2 or >10% loss of 
body weight in the previous 6 months) CP patients re-
ceiving PERT. In this trial, body weight, BMI, and ener-
gy intake increased, with fecal fat decreasing to a similar 
extent in both groups (83). This data clearly shows that 
adequate nutritional management, together with PERT, 
Table 3. — Local complications associated with an 
 inflammatory mass in the pancreatic head
N = 380 patients %
Main pancreatic duct stenosis 39
Common bile duct stenosis 48
Severe duodenal compression 7
Portal vein compression 13
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A bicentric randomized control trial compared ESWL 
alone versus ESWL followed by endoscopic MPD drain-
age in 55 patients (95). Two years after trial intervention, 
a similar proportion of patients experienced complete 
pain relief in both groups. The only significant between-
group differences were a longer hospital stay duration 
and higher treatment cost in the ESWL plus ERCP vs. the 
ESWL alone group (96). The location of obstructive cal-
cifications in the pancreatic head was the only factor in-
dependently associated with absence of pain relapse (95).
3. Pancreatic duct stenting
Pancreatic duct stenting is recommended for treating 
painful CP associated with a dominant MPD stric-
ture (73).
a) What should be the total duration of stenting ?
Statement : Pancreatic stenting should be pursued for 
at least 12 months in patients with persistent pain re-
lief
Criteria used for “definitively” removing a stent are : 
1) adequate contrast medium outflow into the duodenum, 
occurring within 1-2min following ductal filling up-
stream from the dilated stricture, immediately after stent 
removal ; 2) easy passage of a 6Fr catheter through the 
dilated stricture (73). MPD stenting for a short, pre-
defined duration (6 months) has been shown to be poorly 
effective (102). After a 23-month median total duration 
of stenting prior to removal, 62% of patients maintained 
satisfactory pain control without pancreatic stent replace-
ment during a median time of 27 months (103). The ma-
jority of patients with pain recurrence after attempted 
“definitive” stent removal relapsed during the first year 
following stent removal (79%), with almost all (97%) 
having relapsed by 24 months (103). Consequently, if a 
patient remains stable during the first year after stent re-
moval, subsequent relapse and need for re-stenting are 
less likely.
b) How should stent exchange be managed : on-demand 
or systematic ?
Statement : On-demand stent exchange should be the 
preferred strategy
Stent occlusion, the most frequent complication of 
MPD stenting, is treated by stent exchange. This may be 
performed either at regular intervals (i.e., 3 months) or 
“on-demand”, such as in patients with pain recurrence 
and recurrent MPD dilatation (103).
On-demand stent exchange is the preferred strategy, 
as the length of the stent’s clinical effect is rather unpre-
dictable : even when clogged, the stent may remain clini-
cally effective (104). Stent replacement was reported to 
be required after a mean period of 8-12 months using this 
on-demand strategy (105). Longer stent placement 
 administering enzymes appears an attractive option, 
there is no evidence that these are effective in reducing 
pain (91-93).
Medical and nutritional treatment make up the first, 
yet essential, step before any endoscopic or surgical ther-
apy can be considered (83). Conservative management 
may, however, be the only step for patients with no  ductal 
abnormalities, and those with end-stage or asymptomatic 
disease, in whom endoscopy and surgery are not 
 indicated, and may even increase associated morbidity 
and mortality.
V. Endoscopic treatment of chronic pancreatitis
Pain is the CP symptom that most commonly requires 
treatment. It may be related to increased pressure within 
the ductal system or parenchyma secondary to outflow 
obstruction of the main pancreatic duct (MPD).
1. How should the best candidates for initial endoscopic 
treatment be selected ?
Statement : Endoscopic therapy can be considered as 
early as possible in the course of painful CP ; it can be 
combined with extracorporeal shock-wave lithotripsy 
(ESWL) in the presence of large (> 4 mm), obstruc-
tive stone(s) located in the pancreatic head, and with 
ductal stenting in the presence of a single MPD stric-
ture that induces a markedly dilated MPD
The best candidates for endoscopic treatment (ET) are 
symptomatic patients presenting with appropriate mor-
phological features, such as obstructive ductal stone(s), 
ductal stricture(s), or MPD dilatation (94).
Factors independently associated with long-term 
(≥ 2 years) pain relief following ET include : (a) location 
of obstructive calcifications in the pancreatic head ; (b) 
short disease duration ; (c) low frequency of pain attacks 
before ET ; (d) complete MPD stone clearance ; (e) ab-
sence of MPD stricture at initial ET ; (f) alcohol and 
smoking withdrawal during follow-up (73,94-99).
2. How should the best candidates for ESWL alone be 
selected ?
Statement : In uncomplicated CP with radiopaque 
stones ≥ 5 mm obstructing the MPD, ESWL alone 
could be  recommended as the first-line procedure in 
centers with ESWL experience
Patients selected for treatment using ESWL alone are 
those who present with uncomplicated painful CP associ-
ated with at least one calcification ≥ 5 mm located in the 
pancreatic head or body, with upstream MPD dilata-
tion. (95). Two uncontrolled series involving 350 pa-
tients have reported on ESWL used alone in painful CP. 
Spontaneous MPD stone clearance was reported in 70%-
88% of patients, with pain relief observed in 78% of pa-
tients over a mean follow-up of 44 months (100,101).
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be considered, particularly for patients with a poor pre-
dicted outcome following ET (see above) (67). We high-
ly agree with this recommendation (Table 4).
In addition, ET could be performed as a bridge to sur-
gery in the following cases : for patients where surgery is 
the optimal approach but should be delayed until inflam-
matory changes in the pancreatic or peripancreatic area 
have resolved ; to assess response to ductal decompres-
sion as a response predictor of surgery ; for patients who 
initially refused surgery in favor of ET (94).
VI. Surgical treatment of chronic pancreatitis
Indications for surgery are described in Table 4.
1. Types of surgical interventions
Surgical therapy for CP consists of :
a) surgical drainage of obstructed pancreatic body and 
tail (longitudinal pancreatico-jejunostomy) ;
b) resection of pancreatic head or tail (pancreatico-duo-
denectomy or distal pancreatectomy) ;
c) combination technique to drain pancreatic body and 
tail with resection of the inflammatory pancreatic 
head (duodenum preserving pancreatic head resec-
tion according to Frey or Beger) ;
d) total pancreatectomy with islet transplantation, the 
most aggressive, though seldomly performed, surgi-
cal approach.
Drainage-surgery : longitudinal pancreatico-jejunos-
tomy 
In earlier years, the most common drainage surgery 
was longitudinal pancreatico-jejunostomy (LPJ). In this 
procedure, the dilated pancreatic duct is incised over its 
entire length, and a jejunal loop is sutured to the anterior 
surface of the pancreas. This constitutes a rather simple 
procedure with low risk of postoperative complications 
and of exocrine and endocrine insufficiency. In most 
cases, however, this approach has proven insufficient to 
relieve pain, especially when the pancreatic head is not 
adequately drained (107).
 without exchange should be avoided in order to prevent 
complications related to long-standing pancreatic stent 
occlusion.
c) Should single or multiple stents be used ?
Statement : The simultaneous placement of multiple, 
side-by-side, pancreatic stents can be recommended in 
patients with MPD strictures persisting after 12 
months of single plastic stenting
The theoretical advantages of multiple stents consist 
of the following : greater stricture dilatation, lower fre-
quency of simultaneous stent occlusion, possible drain-
age of pancreatic secretions alongside the stents even if 
all stents occlude, potential longer interval between 
stents replacements, and potential higher rate of stricture 
calibration.
In one study (106), the calibration of a single distal 
MPD stricture with multiple stent insertion was observed 
in 95% of 19 patients over a mean 7-month period. After 
a mean 38-month follow-up, 84% remained free of pain.
4. When should surgical options be considered after 
endoscopic treatment ?
Statement : We recommend surgery in the following 
cases : a) technical failure of ET ; b) early (6 to 8 
weeks) clinical failure ; c) definitive biliary drainage 
at a later time ; d) pancreatic ductal drainage when re-
petitive ET is considered unsuitable in young patients ; 
e) resection of a pancreatic inflammatory head where 
pancreatic cancer cannot be ruled out ; f) duodenal ob-
struction. Pancreatic resection may also be indicated 
when the disease (isolated ductal obstruction) is con-
fined to the pancreatic tail
Current guidelines recommend performing ET as ini-
tial approach, with surgery only considered for cases 
where all other measures have failed or when symptoms 
recur (67,73). However, the clinical response to ET 
should be evaluated at 6-8 weeks. If the response is 
deemed unsatisfactory, the patient’s case should be dis-
cussed in a multidisciplinary team involving endosco-
pists, surgeons, and radiologists. Surgical options should 
Table 4. — Surgical intervention after initial endoscopic therapy should be discussed
in a multidisciplinary approach in the following cases
• Technical or early clinical failure of endoscopic therapy
   – Failure of adequate drainage of the main pancreatic duct
   – Unsatisfactory clinical response evaluated after 6-8 weeks following initial endoscopic therapy
   – When repetitive endoscopic therapy is considered too frequent in young patients
   – Disease confined to the tail (isolated duct obstruction)
• Complications at nearby organs
   – Persistent obstruction of duodenum or bile duct due to an enlarged mass in the pancreatic head
   – Inflammatory erosion of arteries surrounding the pancreas unsuccessfully treated by interventional radiologist
• Symptomatic inflammatory mass in the pancreatic head
• Recurrent complaints after initial successful endoscopic therapy
   – When stents are removed definitively after 12-24 months
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– Better postoperative quality of life as compared to 
PD (50).
These techniques are currently considered first-choice 
surgical interventions when dealing with CP.
In a recent meta-analysis, both DPHR techniques were 
shown to be equally safe and effective compared to PD. 
With the Beger procedure, complete pain relief could be 
achieved in a large percentage of patients, yet with a pos-
sibly higher postoperative morbidity. With the Frey pro-
cedure, a significantly lower postoperative morbidity was 
demonstrated, though complete pain relief was less com-
monly achieved when compared to the Beger procedure. 
Conclusively, both new strategies should be recommend-
ed in preference to PD. In terms of quality of life, pancre-
atic exocrine function, and delayed gastric emptying, the 
published results were also in favor of duodenum- 
preserving strategies (112,113).
Total pancreatectomy and islet transplantation
A recent review covering total pancreatectomy fol-
lowed by islet transplantation was based on five subject-
related studies with poor evidence and obvious procedure 
selection bias. For this rather aggressive approach, the 
indication was shown to rely on small duct chronic pan-
creatitis and recurrent pain following celiac plexus block 
or splanchnicectomy. Insulin independence rates ranged 
from 46% to 64% at 5 years and up to 28% at 10 years of 
follow-up. There was a significant reduction in morphine 
requirements and, based on a questionnaire, 79% of pa-
tients felt that surgery had improved their quality of life. 
Results observed concerning pain reduction were equal 
to those noted with other surgical interventions. Factors 
associated with insulin independency were female gen-
der, low body weight, and higher islet equivalents per kg 
of body weight, which, according to the authors, was an 
argument in favor of early referral for this proce-
dure (114).
Resection : pancreatico-duodenectomy and distal 
pancreatectomy
When performing a pancreatico-duodenectomy (PD), 
the diseased pancreatic head and surrounding duodenum 
are removed along with the inflamed neural tissue and 
mesoduodenum. This approach, which has been shown 
to be effective in treating chronic pain, is certainly indi-
cated in cases of suspected malignancy or groove pancre-
atitis. Yet long-term postoperative morbidity after PD is 
significant, involving up to 20% of cases (108).
When performing a distal pancreatectomy (DP), the 
diseased distal pancreas is removed. As this technique 
often results in exocrine and endocrine insufficiency, it is 
only indicated in cases of suspected malignancy or in the 
presence of pancreatic tail obstruction.
Drainage-resection-technique : duodenum preserv-
ing pancreatic head resection (DPHR)
In duodenal-preserving pancreatic head resection 
(DPHR), two techniques are described in the surgical lit-
erature : Beger technique (Fig. 1) and Frey technique 
(Fig. 2). In both techniques, the diseased pancreatic head 
is partially excised, with the duodenum and intrapancre-
atic bile duct left intact. On the cut surface and pancre-
atic tail, a jejunal loop is sutured so as to drain the entire 
pancreas (109,110).
The technique’s advantages are as follows :
– Only one single anastomosis has to be performed to 
drain the entire pancreas ;
– Duodenum and intrapancreatic bile duct remain un-
touched, with advantageous consequences on post-
operative nutritional status and gastric emptying ;
– Superior results in resolving chronic pain as compared 
to PD ;
– Improved exocrine and endocrine function preserva-
tion as compared to PD (111) ;
Fig. 1. — Duodenum and bile duct preserving pancreatic 
head resection according to Beger (CBD : common bile 
duct).
Fig. 2. — Duodenum and bile duct preserving pancreatic 
head resection according to Frey (CBD : common bile 
duct, VMS : superior mesenteric vein).
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Until recently, the causes of CP in children were 
thought to be idiopathic (51-73.8%), traumatic (10-35%), 
biliary including congenital malformations like choleco-
cal cyst or anomalous pancreatobiliary junction (14-
19%), drug-related (< 10%), hereditary (5-8%), meta-
bolic (2-7%), and other (< 2%). There has been growing 
evidence that the contribution of genetic or hereditary 
causes has been underestimated. These etiological fac-
tors may, in fact, be responsible for a significant propor-
tion of cases previously diagnosed as idiopathic 
[118,119]. Pediatric onset CP with a contributory genetic 
etiology is primarily related to CFTR (14-69%), SPINK 
(27-57.3%), and PRSS 1 (9.3-24%) mutations. CTRC 
may also be a putative gene, yet given that screening for 
this gene has only been routinely available for a short 
time, this association frequency remains unknown. 
Moreover, different studies highlight that heterozygous 
mutations in CFTR with SPINK or PRSS1 may have an 
additive effect in its contributory role in genetically-de-
termined CP. In this context, systematic screening for 
mutations in all four of these genes should be performed 
in children with CP, irrespective of family histo-
ry (118,119). Furthermore, the systematic search for sen-
sitizing factors, such as passive tobacco exposure, should 
be performed. 
Clinical presentation of pancreatitis in children is sim-
ilar to that of adults. However, young children cannot 
verbalize their complaints, which often results in a de-
layed diagnosis. Pediatricians should therefore be aware 
of the possibility of pancreatic pathologies in this specific 
population (117,120). To date, only scarce data has been 
available that determines the best imaging modality for 
CP diagnosis in children. However, ultrasonography re-
mains the preferred first-line imaging technique, though 
the technique is operator-dependent. MRCP after secretin 
administration seems to be the technique of choice for 
further imaging in CP. It is worth noting that MRCP 
needs to be performed under narcosis in children under 
6 years, as movement or anatomical particularities (small 
caliber of non-dilated ducts and poor parenchymal  signal) 
may render the examination poorly contributive. CT scan 
is not routinely recommended to evaluate pancreatitis in 
children, as it is associated with high-radiation  exposure. 
The role of EUS or ERCP in CP diagnosis must 
2. Endoscopic or surgical treatment
Statements : Duodenopancreatectomy or oncological 
 distal pancreatectomy should be considered in cases 
of suspected malignancy
Drainage surgery in combination with limited pancre-
atic head resection (duodenum preserving) appears to 
be the best surgical strategy in most chronic pancreati-
tis patients exhibiting early complications or recurrent 
complaints after endoscopic therapy
Two prospective randomized studies have addressed 
the longstanding dispute whether either endoscopic or 
surgical intervention should be the preferred approach in 
CP treatment. According to Dite et al. (56), 34% of the 
surgically-treated patients were pain-free after 5 years, as 
compared to 15% of the endoscopically-treated patients. 
Nutritional status was shown to be superior in the surgi-
cally-treated group, with new onset diabetes being com-
parable in both groups. A second report from Cahen et 
al. (57) showed that 32% of the endoscopically-treated 
patients exhibited improved pain complaints versus 75% 
of the surgically-treated patients. Complication ratio, 
length of hospital stay, and pancreatic function were sim-
ilar in both groups, though the endoscopically-treated 
patients underwent more procedures (Table 5).
These studies underline the role of the surgical ap-
proach in CP treatment. Correct patient selection in a 
multidisciplinary approach and appropriate timing for 
referral to surgery are key to a successful outcome (115).
VII. Chronic pancreatitis in children
1. What are the specificities of chronic childhood 
 pancreatitis ?
Statement : Pediatricians should be aware of and sys-
tematically search for CP in the differential diagnosis 
of chronic abdominal pain. Clinicians should attempt 
to  determine CP etiology 
Pancreatitis is a rare clinical entity in children, with an 
estimated incidence of approximately 4-13/100,000 (116).
Recurrence likely occurs in 10% of these  patients (117).
Table 5. — Comparison of endoscopic and surgical results in 
 chronic pancreatitis based on two randomized trials (56,57)
Endoscopy Surgery
Izbicki pain score P < 0.001 51 ± 23 25 ± 15
Technical success P < 0.001   53% 100%
Complications P = 0.15 58% 35%
Procedures P = < 0.001 8 (1-21) 3 (1-9)
Diagnostic 3 (0-11) 2 (0-8)
Therapeutic 5 (1-11) 1 (1-5)
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displayed a sensitivity of 100% and specificity of 
95% (124,125). The 13C-MTG is a sensitive (89%) and 
specific (81%) test to evaluate steatorrhea in mild to 
moderate disease, and to assess the efficacy of pancreatic 
enzyme replacement therapy (PERT) (126). This investi-
gation, however, requires local validation and is time-
consuming. Of the remaining indirect function tests, fe-
cal elastase-1 (< 200µg/g stool) is more accurate in 
moderate to severe insufficiency, and its simplicity and 
convenience make it a useful test. In addition, fecal elas-
tase results are independent of PERT (122,67).
2. In which chronic pancreatitis patients is it recom-
mended to screen for pancreatic exocrine insufficiency ?
Statement : Every patient with a diagnosis of chronic 
pancreatitis should be screened for PEI
In recent guidelines, there is no consensus on the pre-
cise timing for PEI screening in PC patients. It seems, 
however, crucial to assess the patient’s nutritional status, 
as the severity of a pre-existing or developing malnutri-
tion likely affects outcome and vital prognosis.
Clinical symptoms of steatorrhea are observed rela-
tively late in the course of CP, and even in late stages, 
steatorrhea may be much more common than based only 
on clinical grounds (67). Due to symptoms being poten-
tially absent or mimicking other diseases, a routine blood 
test with serum nutritional markers is often helpful as an 
initial step when malabsorption is suspected, although 
blood tests alone should not be considered as sufficient to 
establish a diagnosis (123). 
3. What are the clinical/nutritional consequences of 
pancreatic exocrine insufficiency ?
Statement : Subclinical or clinical steatorrhea may 
lead to micronutrient deficiencies and malnutrition
Maldigestion of dietary macronutrients (fat, proteins, 
and carbohydrates) leads to malnutrition. The main clini-
cal manifestations of PEI are fat malabsorption (com-
monly manifesting as steatorrhea), weight loss, abdomi-
nal discomfort, and distension. Overt steatorrhea 
(characterized by voluminous, yellowish, and foul-smell-
ing stool) occurs in approximately one-third of CP pa-
tients (127). Steatorrhea is usually observed prior to pro-
tein deficiencies, as lipolytic activity decreases faster 
than proteolysis (128). Steatorrhea is distressing, socially 
embarrassing, and may facilitate the occurrence of hyp-
eroxaluria, urinary oxalate stones, and renal insufficien-
cy (8). This condition may also impact working ability, 
cognitive functioning, financial strain, and overall 
QoL (129).
In addition, malabsorption of fat-liposoluble vitamins 
(A, D, E, and K) may occur, yet clinically-symptomatic 
vitamin deficiencies are rare (82,130,131). Nevertheless, 
almost one in four CP patients exhibit osteoporosis, 
while almost two-thirds have either osteoporosis or 
 particularly be discussed in young children, as other tech-
niques may be less invasive and thus favored for estab-
lishing the diagnosis (120).
2. What are the childhood-specific therapeutic options ?
Statement : There is a lack of specific treatment guide-
lines for CP in the pediatric population. First-line 
medical treatment should be conservative, while 
ERCP can be considered for ductal drainage
The medical treatment of CP in children is initially 
conservative, consisting of withholding fatty food and 
controlling pain. Based on expert opinion, non-steroidal 
anti-inflammatory drugs and acetaminophen are first-line 
agents for pain control. Narcotics can be considered as 
second-line drugs. Pancreatic enzyme supplementation 
to reduce the feed-back loop of exocrine pancreatic acti-
vation is a controversial technique. The usefulness of an-
tioxidants in pediatric CP has not yet been evaluated. 
ERCP is indicated in the treatment of symptomatic ductal 
strictures and pancreatic stones. Ductal decompression 
can be obtained by performing sphincterotomy or stone 
extraction with stent placement (120,121). Pancreatic 
surgery is rarely indicated for childhood CP and is re-
served for patients that do not respond to medical or en-
doscopic therapy (120).
VIII. Complications : pancreatic exocrine insuf-
ficiency
1. How should we assess mild/moderate/severe pancre-
atic exocrine insufficiency ?
Statement : There is no optimal test to assess pancre-
atic exocrine insufficiency. The 3-day fecal fat test, 
though unpopular, is considered the gold standard. 
Suitable alternatives are fecal acid steatocrit or fecal 
elastase tests
There are numerous available procedures to evaluate 
pancreatic exocrine insufficiency (PEI), but the fact that 
so many exist indicates that none reliably detect PEI. In 
clinical practice, PEI diagnosis is usually based on pa-
tient’s clinical state assessment, self-reporting of bowel 
movements, as well as weight loss in adults and failure to 
thrive in children. A trial with pancreatic enzyme re-
placement resulting in symptom improvement would 
support a PEI diagnosis (122,123). In Belgium, however, 
reimbursement for pancreatic enzymes requires proof of 
PEI.
The 3-day fecal fat test is considered the gold standard 
for diagnosing and quantifying steatorrhea, but this pro-
cedure is unpopular with patients and laboratory techni-
cians (122). A suitable alternative is the stool acid steato-
crit determined on spot samples from a 24-hour stool 
collection, a reliable, easy, and inexpensive test, which, 
when compared with 72-hour stool quantitative fecal fat, 
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Diet counseling is best achieved with the involvement 
of a specialized dietician (83). Her/his role is to make a 
full assessment of the patient’s nutritional habits, includ-
ing total energy, fat, and protein intake, as well as to ad-
vise improvements and monitor compliance and results.
5. How should pancreatic exocrine insufficiency be 
treated ?
Statement : Enzyme replacement therapy is beneficial 
for symptomatic patients, but also in cases of subclini-
cal insufficiency. Enteric-coated preparations should 
be taken with each meal or snack containing fat, and 
dosage should be adapted to the meal’s fat content. 
Weight gain and symptom improvement correlate 
with adequate enzyme use
Pancreatic enzyme replacement therapy is recom-
mended for patients with clinical features of exocrine in-
sufficiency or with proven pancreatic insufficien-
cy (138,139). Enzyme supplementation should certainly 
be started in symptomatic patients with steatorrhea, diar-
rhea, and weight loss, with the aim of suppressing mal-
digestion and malabsorption and restoring adequate nu-
trition and weight gain. In cases of subclinical exocrine 
insufficiency (symptom-free but abnormal testing), treat-
ment is also recommended.
The only pancreatic enzyme preparation is a porcine 
extract encapsulated in enteric-coated mini-micro-
spheres (140). The preparation is available in capsules of 
three different strengths : Creon 10,000, 25,000, and 
40,000 lipase U.
In adults, the initial dosage recommended is 25,000-
40,000 units of lipase with every meal, and 10-25,000 
units of lipase with snacks. Dosage can then be titrated 
up to a maximum of 10,000 units/Kg/day (141,142). In 
children, the initial recommended dosage is 1000 units/
Kg/meal.
Pancreatic enzymes should be taken during all meals 
or snacks containing fat. Fat-free snacks like fruits, jelly, 
or juices do not require enzyme intake (143). Patients 
should be educated to modulate pancreatic enzyme dos-
age according to the meals’ fat content. Self-dosing of 
pancreatic enzymes correlates with improved symptom 
relief (144).
The treatment response is measured clinically by 
weight gain and improvement in symptoms like steator-
rhea. When symptoms of exocrine insufficiency persist 
in spite of adequate PERT, function tests (mixed triglyc-
erides breath, acid steatocrit, and quantitative fecal fat) 
are indicated in order to evaluate treatment effica-
cy (126,145,146).
6. What should be done in cases of unsatisfactory clini-
cal response ?
Statement : In cases of unsatisfactory clinical re-
sponse, compliance and adequate use of enzymes 
should be checked, proton pump inhibitors added, and 
other malabsorption syndromes ruled out
 osteopenia due to vitamin D deficiency (132), malab-
sorption of calcium, poor dietary intake, or other factors 
like smoking. Therefore, calcium and vitamin D supple-
mentation, as well as regular monitoring of bone health, 
should be an integral part of CP nutrition manage-
ment (81). Vitamin E deficiency may occur more often 
than that of vitamin A, D, and K, potentially affecting as 
many as 75% of cases. This deficiency may be more 
prevalent in the presence of steatorrhea, malnutrition, 
and alcoholic CP, regardless of dietary intake. Impaired 
night vision has also been observed (133).
Specific deficiencies in calcium, magnesium, zinc, 
prealbumin, iron, thiamine, vitamin B12, folic acid, and 
essential fatty and amino acids have also been report-
ed (134). These may lead to tetany, glossitis, and cheilo-
sis, and even to peripheral neuropathy in a more progres-
sive stage. Furthermore, reduced plasma lipoprotein 
levels can increase the risk of cardiovascular events (ar-
terial involvement, coronary heart disease, and aortic cal-
cifications), independently of lifestyle factors (135). 
Moreover, qualitative fat maldigestion might clinically 
impact glucose metabolism, and exocrine disease might 
enhance the risk of diabetes mellitus (136).
4. Which dietary management should be used for pan-
creatic exocrine insufficiency ?
Statement : Patients should follow a healthy balanced 
diet taken in short meals and snacks, with a normal fat 
content. Medium-chain triglycerides are not recom-
mended in first intention
Although there is no specific diet to follow, patients 
should be advised to pursue a well-balanced diet in line 
with the “food pyramid chart”. Fat restriction is no longer 
advocated (16,67,82,83). Low-fat diets are inferior in 
terms of total energy, and restricting fat intake also re-
duces the intake of fat-soluble vitamins. Patients should 
be advised to consume an at least normal fat intake (e.g., 
30% energy from fat). All meals and snacks should con-
tain some fat in order to spread the recommended fat in-
take over the whole day.
Frequent small meals should be preferred and alcohol 
stopped. Six or more smaller meals throughout the day, 
combined with suitable enzyme therapy, likely reduce 
the risk of residual fat malabsorption. Smaller meals and 
snacks exhibit better tolerance (less anorexia and nausea), 
along with more efficient gastric mixing, as well as simul-
taneous gastric emptying of the chyme with enzymes.
Medium-chain triglycerides are not recommended in 
the first stages (137). Despite theoretical benefits (pan-
creatic enzymes or bile unnecessary for absorption), they 
do not provide any clear nutritional advantage over the 
usual long-chain triglycerides in patients using pancreat-
ic enzymes. Moreover, they are poorly tolerated in many 
patients, as they are associated with side-effects such as 
abdominal pain, nausea, and diarrhea. Medium-chain tri-
glycerides are, therefore, rarely used.
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Statement : Follow-up should be implemented in pa-
tients with chronic pancreatitis, primarily in order to 
detect subclinical maldigestion and the development 
of pancreatogenic diabetes
Patient follow-up should be concerned with the devel-
opment of endocrine and exocrine insufficiency, effec-
tiveness of ductal drainage, detection of local complica-
tions, and screening for cancer (for specific etiologies, 
such as hereditary pancreatitis) (67,73,76,81,157,131). 
CP is an ongoing process that may not be altered by any 
treatment except total pancreatectomy. Follow-up is 
therefore mandatory and should include clinical features 
(weight loss and steatorrhea), nutritional parameters, and 
metabolic abnormalities (diabetes, osteopenia, and hyp-
eroxaluria). Clinical check-up (including body weight 
and BMI) and laboratory follow-up (including glycemia, 
complete blood count, comprehensive metabolic panel, 
international normalized ratio, as well as levels of albu-
min, prealbumin, vitamin D, and carotene or other fat-li-
posoluble vitamins) every 6-12 months seem reason-
able (157). Patients with exocrine insufficiency and risk 
factors (frail patients and smokers) should undergo bone 
densitometry, on a case-by-case basis, because of the risk 
of osteopenia or osteoporosis due to vitamin D deficien-
cy.
Should we consider differences in the follow-up be-
tween medical, endoscopic, or surgical treatments ? Dif-
ferences may first relate to the disease severity when 
treatment is undertaken, type of surgery (drainage vs. re-
section) used, as well as completeness of endoscopic 
drainage and stone extraction. Surgery may induce dete-
rioration of endocrine function resulting in a more un-
stable form of pancreatogenic diabetes. The placement of 
stents via endoscopy induces a need for stent patency 
control by means of regular CT scan or MRI. This should 
equally be a good opportunity for further dietary counsel-
ing and advising patients to stop smoking.
2. What are the effects of ductal drainage (by endo-
scopic or surgical means) on the natural history of 
chronic pancreatitis, especially regarding endocrine and 
exocrine pancreatic functions ?
Statement : There is no evidence for treating asymp-
tomatic patients with morphological features of chron-
ic  pancreatitis
There are only a few studies reporting long-term ef-
fects on pancreatic function following endoscopic or sur-
gical therapy, and the results are conflicting (96,98,158-
160). Currently, therefore, there is no consensus on the 
long-term effects of surgery and endoscopy on pancreatic 
endocrine and exocrine function. The natural disease his-
tory remains related to the factors leading to inflamma-
tion and fibrosis, and particularly alcohol and smoking 
continuation.
In cases of unsatisfactory clinical response, dosage of 
pancreatic enzymes should be optimized, and compli-
ance and adequate use of pancreatic enzymes checked. 
Otherwise, acid-suppressing agents (proton pump inhibi-
tors) should be added at a standard dose (145).
If the patient is still not responding to treatment, other 
malabsorption syndromes (such as Giardia infestation, 
coeliac disease, bacterial overgrowth, and cholestasis) 
must be ruled out (146).
IX. Complications : pancreatogenic diabetes
1. What are the specificities of diabetes secondary to 
chronic pancreatitis ?
Patients with pancreatic endocrine insufficiency, ab-
normal pancreatic imaging, and absence of diabetes-as-
sociated antibodies are classified as pancreatogenic or 
Type 3c diabetes (T3cDM) according to the American 
Diabetes Association classification (147). Diabetes mel-
litus has been observed in 26-80% of CP patients (148). 
Hyperglycemia is typically relatively mild, yet blood 
glucose control may be labile due to the loss of glucagon 
response to hypoglycemia, carbohydrate malabsorption, 
and inconsistent eating patterns associated with pain or 
nausea. T3cDM often presents as brittle diabetes (149-
151). In these cases, complications like macro- or micro-
angiopathy, nephropathy, neuropathy, and retinopathy 
are as common as in Type 1 diabetes patients. CP and 
diabetes are both risk factors for developing pancreatic 
cancer (152).
2. What is the recommended treatment for pancreato-
genic diabetes ?
There is a lack of data for evidence-based practice in 
these patients. As the principal endocrine defect is insulin 
deficiency, insulin therapy is the preferred treatment for 
most patients, in compliance with general insulin dosing 
and regimen guidelines for Type 1 diabetes. Given that 
the degree of insulin deficiency is dependent on disease 
severity and duration, controlling mild hyperglycemia 
using oral hypoglycemic agents early in the disease 
course may be a valid approach. Many T3cDM patients 
are initially treated with metformin as drug of first 
choice (151,152). In a retrospective study, metformin has 
been shown to reduce the risk of pancreatic cancer by 
70% (153). In addition, this drug was reported to be as-
sociated with a significant reduction in cancer-related 
mortality (154,155). However, more studies are warrant-
ed before a definite conclusion can be made as to the rec-
ommendation of metformin for oncologic considerations.
X. Follow-up
1. How should a patient with chronic pancreatitis treated 
by medical, endoscopic, or surgical therapy be followed 
up ?
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addition, late mortality may be related to other cancers, 
such as oropharyngeal, lung, and esophageal tumors, 
which are also linked to alcohol use and smoking behav-
ior.
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